Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series

BMC Dermatol. 2005 Aug 18;5:9. doi: 10.1186/1471-5945-5-9.

Abstract

Background: Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today.

Case presentations: We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD11a), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-alpha).

Conclusion: These cases are presented to characterize this "flare" reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Psoriatic / drug therapy
  • CD11 Antigens
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Lymphocyte Function-Associated Antigen-1 / immunology*
  • Male
  • Middle Aged
  • Patient Compliance
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Secondary Prevention

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CD11 Antigens
  • Immunologic Factors
  • Lymphocyte Function-Associated Antigen-1
  • efalizumab